NT-proBNP provides incremental prognostic information in cardiac outpatients with and without echocardiographic findings

Clinical Cardiology

Volumn 34, Issue 3, 2011, Pages 183-188

  Toggweiler, Stefan ^a   Borst, Oliver ^a   Enseleit, Frank ^a   Hermann, Matthias ^a   Ruschitzka, Frank ^a   Lüscher, Thomas F ^a   Noll, Georg ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; ARTICLE; CONGENITAL HEART DISEASE; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY DISEASE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTPATIENT CARE; PROGNOSIS; RESTRICTIVE CARDIOMYOPATHY; RETROSPECTIVE STUDY; VALVULAR HEART DISEASE;

ADULT; AGED; CORONARY ARTERY DISEASE; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HEART VALVE DISEASES; HUMANS; MALE; MIDDLE AGED; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; OUTPATIENTS; PEPTIDE FRAGMENTS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 79952724852     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20894     Document Type: Article

References (29)

1. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet. 1998;351:9-13. (Pubitemid 28020159)
2. Mottram PM, Leano R, Marwick TH. Usefulness of B-type natriuretic peptide in hypertensive patients with exertional dyspnea and normal left ventricular ejection fraction and correlation with new echocardiographic indexes of systolic and diastolic function. Am J Cardiol. 2003;92:1434-1438. (Pubitemid 37532566)
3. Mueller C, Breithardt T, Laule-Kilian K, et al. The integration of BNP and NT-proBNP into clinical medicine. Swiss Med Wkly. 2007;137:4-12. (Pubitemid 46191225)
4. Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90:195-203. (Pubitemid 24203680)
5. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004;350:647-654. (Pubitemid 38364623)
6. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007;50:2357-2368. (Pubitemid 50011582)
7. Maeda K, Tsutamoto T, Wada A, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol. 2000;36:1587-1593.
8. Lancellotti P, Moonen M, Magne J, et al. Prognostic effect of long-axis left ventricular dysfunction and B-type natriuretic peptide levels in asymptomatic aortic stenosis. Am J Cardiol. 2010;105:383-388.
9. Potocki M, Mair J, Weber M, et al. Relation of N-terminal pro-B-type natriuretic peptide to symptoms, severity, and left ventricular remodeling in patients with organic mitral regurgitation. Am J Cardiol. 2009;104:559-564.
10. Pizarro R, Bazzino OO, Oberti PF, et al. Prospective validation of the prognostic usefulness of brain natriuretic peptide in asymptomatic patients with chronic severe mitral regurgitation. J Am Coll Cardiol. 2009;54:1099-1106.
11. Nessmith MG, Fukuta H, Brucks S, et al. Usefulness of an elevated B-type natriuretic peptide in predicting survival in patients with aortic stenosis treated without surgery. Am J Cardiol. 2005;96:1445-1448. (Pubitemid 41566630)
12. Koch A, Zink S, Singer H. B-type natriuretic peptide in paediatric patients with congenital heart disease. Eur Heart J. 2006;27:861-866.
13. Allanore Y, Meune C. N-terminal pro brain natriuretic peptide: the new cornerstone of cardiovascular assessment in systemic sclerosis. Clin Exp Rheumatol. 2009;27:59-63.
14. McCullough PA, Sandberg KR. B-type natriuretic peptide and renal disease. Heart Fail Rev. 2003;8:355-358. (Pubitemid 37548056)
15. Hogenhuis J, Voors AA, Jaarsma T, et al. Anaemia and renal dysfunction are independently associated with BNP and NT-proBNP levels in patients with heart failure. Eur J Heart Fail. 2007;9:787-794. (Pubitemid 47212827)
16. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation. 2000;102:865-870.
17. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004;350:655-663. (Pubitemid 38364624)
18. Linssen GCM, Bakker SJL, Voors AA, et al. N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. Eur Heart J. 2010;31:120-127.
19. Galasko GIW, Lahiri A, Barnes SC, et al. What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease? Eur Heart J. 2005;26:2269-2276. (Pubitemid 41541390)
20. Gardin JM, Adams DB, Douglas PS, et al. Recommendations for a standardized report for adult transthoracic echocardiography: a report from the American Society of Echocardiography's nomenclature and standards committee and task force for a standardized echocardiography report. J Am Soc Echocardiogr. 2002;15:275-290. (Pubitemid 44970067)
21. Grewal J, McKelvie RS, Persson H, et al. Usefulness of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. Am J Cardiol. 2008;102:733-737.
22. Valle R, Aspromonte N, Feola M, et al. B-type natriuretic peptide can predict the medium-term risk in patients with acute heart failure and preserved systolic function. J Card Fail. 2005;11:498-503. (Pubitemid 41403272)
23. Paul B, Soon KH, Dunne J, et al. Diagnostic and prognostic significance of plasma N-terminal-pro-brain natriuretic peptide in decompensated heart failure with preserved ejection fraction. Heart Lung Circ. 2008;17:497-501.
24. O'Connor CM, Hasselblad V, Mehta RH, et al. Triage after hospitalization with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score. J Am Coll Cardiol. 2010;55:872-878.
25. Andersson SE, Edvinsson ML, Bjork J, et al. High NT-proBNP is a strong predictor of outcome in elderly heart failure patients. Am J Geriatr Cardiol. 2008;17:13-20.
26. O'Hanlon R, O'Shea P, Ledwidge M, et al. The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. J Card Fail. 2007;13:50-55. (Pubitemid 46330833)
27. Bruins S, Fokkema MR, Romer JW, et al. High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 2004;50:2052-2058. (Pubitemid 39425842)
28. Maisel A, Mueller C, Adams K Jr, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008;10:824-839.
29. Wozakowska-Kaplon B, Opolski G, Herman Z, et al. Natriuretic peptides in patients with atrial fibrillation. Cardiol J. 2008;15:525-529.